

This table is dedicated to performance measures around bipolar disorder or bipolar disorder with comorbid diagnoses. These measures include *disease management* (ongoing course of treatment), *social support* (evaluating the use of education and outside support—i.e. family, friends, community—which helps the consumer understand their illness and increases the rate of overall compliance and improved prognosis), and *physical health complications* associated with bipolar disorder and its treatment (indicators examine the rate of glucose regulation and weight gain as a result of glucose metabolism and increased rates of diabetes). More detailed information about each measure maybe found on the “All Measures” Spreadsheet.

Origin	Title	Description
CQAIMH	Use of Mood Stabilizers for Bipolar Disorder	
CQAIMH	Bipolar Disorder: Monitoring change in symptom complex	This measure assesses the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their symptom complex within 12 weeks of initiating treatment.
CQAIMH	Bipolar Disorder: Monitoring for extrapyramidal symptoms	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with an antipsychotic agent who were assessed for the presence of extrapyramidal symptoms twice within the first 24 weeks of treatment.
CQAIMH	Bipolar Disorder: Monitoring lithium serum levels	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with lithium who have evidence of a lithium serum medication level within 12 weeks of beginning treatment.
CQAIMH	Bipolar Disorder: Monitoring for weight gain	This measure assesses the percentage of patients with bipolar disorder who were monitored for weight gain during initial 12 week period of treatment.
CQAIMH	Bipolar Disorder: Recommending adjunctive psychosocial interventions	This measure assesses the percentage of patients with bipolar disorder who receive a recommendation for an adjunctive psychosocial intervention, including evidence-based therapies, within 12 weeks of initiating treatment.
CQAIMH	Bipolar Disorder: Monitoring change in level-of-functioning	This measure assesses the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their level-of-functioning in response to treatment.
CQAIMH	Bipolar Disorder: Use of antimanic agent in BD I with mania/hypomania, mixed, or cycling	This measure assesses the percentage of patients with BD I with mania/hypomania, mixed or cycling symptoms and behaviors who have evidence of use of a pharmacotherapy agent with antimanic properties during the first 12 weeks of treatment.
CQAIMH	Bipolar Disorder: Use of mood stabilizing or antimanic agent in BD I with depression	This measure assesses the percentage of patients with Bipolar I Disorder with depressive symptoms and behaviors who have evidence of use of a mood stabilizing or antimanic agent during the first 12 weeks of pharmacotherapy treatment.
CQAIMH	Bipolar Disorder: Avoidance of antidepressant monotherapy in BD I	This measure assesses the percentage of patients with BD I symptoms and behaviors who received monotherapy with an antidepressant agent during the first 12 weeks of treatment.
NQMC	Bipolar disorder: percentage of patients with Bipolar I Disorder with depressive symptoms and behaviors who have evidence of use of a mood stabilizing or antimanic agent during the first 12 weeks of pharmacotherapy treatment.	This measure is used to assess the percentage of patients with Bipolar I Disorder with depressive symptoms and behaviors who have evidence of use of a mood stabilizing or antimanic agent during the first 12 weeks of pharmacotherapy treatment.
CQAIMH	Side Effect Monitoring with Mood Stabilizers	CQAIMH
NQF #0110	Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use	Percentage of patients with depression or bipolar disorder with evidence of an initial assessment that includes an appraisal for alcohol or chemical substance use
NQF #0109	Bipolar Disorder and Major Depression:	Percentage of patients treated for depression who were assessed, prior to treatment, for the presence of current and/or

	Assessment for Manic or hypomanic behaviors	prior manic or hypomanic behaviors.
NQF #0111	Bipolar Disorder: Appraisal for risk of suicide	Percentage of patients with bipolar disorder with evidence of an initial assessment that includes an appraisal for risk of suicide.
NQF # 0112	Bipolar Disorder: Level-of-function evaluation	Percentage of patients treated for bipolar disorder with evidence of level-of-function evaluation at the time of the initial assessment and again within 12 weeks of initiating treatment
NQF # 0580	Bipolar antimanic agent	This measure identifies the percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.
CQAIMH	Bipolar Disorder: Providing condition-specific education and information	This measure assesses the percentage of patients diagnosed and treated for bipolar disorder who are provided with education and information about their illness and treatment within 12 weeks of initiating treatment.
CQAIMH	Bipolar Disorder: Screening for hyperlipidemia when atypical antipsychotic agent prescribed	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with an atypical antipsychotic agent who received at least one assessment for hyperlipidemia within the initial 16 week period of treatment.
NQF #0003	Bipolar Disorder: Assessment for diabetes	Percentage of patients treated for bipolar disorder who are assessed for diabetes within 16 weeks after initiating treatment with an atypical antipsychotic agent.
CQAIMH	Blood Level Monitoring with Mood	CQAIMH
NQMC	Bipolar Disorder: Screening for hyperglycemia when atypical antipsychotic agent prescribed	This measure assesses the percentage of patients diagnosed with bipolar disorder and treated with an atypical antipsychotic agent who receive at least one screening for hyperglycemia within the initial 16 weeks of treatment.
NQMC	Smoking : the percentage of patients with any or any combination of the following conditions: coronary heart disease (CHD), stroke or transient ischaemic attack (TIA), hypertension, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), asthma, schizophrenia, bipolar affective disorder or other psychoses who smoke whose notes contain a record that smoking cessation advice or referral to a specialist service, where available, has been offered within the previous 15 months.	This measure is used to assess the percentage of patients with any or any combination of the following conditions: coronary heart disease (CHD), stroke or transient ischaemic attack (TIA), hypertension, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), asthma, schizophrenia, bipolar affective disorder or other psychoses who smoke whose notes contain a record that smoking cessation advice or referral to a specialist service, where available, has been offered within the previous 15 months.
NQMC	Smoking : the percentage of patients with any or any combination of the following conditions: coronary heart disease (CHD), stroke or transient ischaemic attack (TIA), hypertension, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in	This measure is used to assess the percentage of patients with any or any combination of the following conditions: coronary heart disease (CHD), stroke or transient ischaemic attack (TIA), hypertension, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the previous 15 months.

	the previous 15 months.	
NQF #1927	Cardiovascular health screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications	The percentage of individuals 18 – 64 years of age with schizophrenia or bipolar disorder who were prescribed any antipsychotic medication who received a cardiovascular health screening during the measurement year. [Please note this measure is appropriate for Health Plan Measurement only.]
NQF #1932	Diabetes screening for people with schizophrenia or bipolar disorder who are prescribed antipsychotic medications (SSD)	The percentage of individuals 18 – 64 years of age with schizophrenia or bipolar disorder, who were dispensed any antipsychotic medication and had a diabetes screening during the measurement year. [Please note this measure is appropriate for Health Plan and State level measurement only.]